Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR T Cells and Acalabrutinib in Relapsed or Refractory Mantle Cell Lymphoma
NCT04484012Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Dec 2020
- Primary completion
- Feb 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19CAR-CD28-CD3zeta-EGFRt in mantle cell lymphoma (MCL), sponsored by City of Hope. Started Dec 2020; status: active, not recruiting.
02
Drugs
CD19CAR-CD28-CD3zeta-EGFRt
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04484012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04484012.